Why the study?
Does hyperfractionated accelerated re-irradiation (HART) improve survival in patients with secondary angiosarcoma after breast-conserving therapy?
Population
Patients with secondary angiosarcoma after breast-conserving therapy (BCT)
Comparison
Hyperfractionated accelerated re-irradiation vs Surgery only, conventional radiation therapy, or…
Design
Cohort
Authors
Loading...
HART was associated with better survival in secondary angiosarcoma; leaves open need for randomized confirmation before practice change.
Does hyperfractionated accelerated re-irradiation (HART) improve survival in patients with secondary angiosarcoma after breast-conserving therapy?
HART improves survival outcomes in patients with secondary angiosarcoma after breast-conserving therapy and is well tolerated.
Smith et al. (2013) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: